Overview

Location [1]
12q13.3
Protein [2]
DNA damage-inducible transcript 3 protein
Synonyms [1]
CHOP-10, C/EBPzeta, GADD153, CHOP10, AltDDIT3, CEBPZ, CHOP

DNA-damage-inducible transcript 3 (DDIT3) is a gene that encodes a transcription factor protein that functions as dominant negative inhibitor of DNA binding activity in C/EBP and liver activator proteins. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, lung cancer, and skin cancer.

DDIT3 is altered in 0.16% of all cancers with myxoid liposarcoma, breast invasive ductal carcinoma, lung adenocarcinoma, glioblastoma, and liposarcoma having the greatest prevalence of alterations [3].

DDIT3 GENIE Cases - Top Diseases

The most common alterations in DDIT3 are DDIT3 Fusion (0.07%), DDIT3-FUS Fusion (0.06%), DDIT3 Mutation (0.20%), DDIT3 R156C (0.13%), and DDIT3-EWSR1 Fusion (0.01%) [3].

DDIT3 GENIE Cases - Top Alterations

Significance of DDIT3 in Diseases

Myxoid Liposarcoma +

Liposarcoma +

Malignant Solid Tumor +

Non-Hodgkin Lymphoma +

Soft Tissue Sarcoma +

Round Cell Liposarcoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.